This study tests a new medicine called lonigutamab for people with Thyroid Eye Disease (TED). TED makes eyes bulge and causes discomfort. The study is in Phase 1/2, which means researchers are trying to understand if lonigutamab is safe and helps with TED symptoms.
To join, you must be 18 to 75 years old and have eye bulging of 3 mm or more. You should have TED symptoms that started before joining the study and a Clinical Activity Score (CAS) of 4 or higher, which helps doctors measure how active your TED is. You must agree to use effective birth control if you can have children.
You cannot join if you have certain other health conditions like inflammatory bowel disease, hearing problems, or diabetes. Also, if you've had certain treatments like steroids or other TED medicines, you might not be eligible.
- Duration: The study involves multiple doses, but specific time details are not given.
- Visits: Participants may need to visit multiple centers as part of the study.
- Risks: Possible risks include side effects from the medication.